![OGSIVEO FDA-Approval Featured Image](https://dtrf.org/wp-content/uploads/2023/11/breaking-news-niro-FDA-approval-featured-image-2-720x450.png)
Featured News
FDA APPROVES OGSIVEO™ (NIROGACESTAT), AS THE FIRST MEDICAL THERAPY FOR THE TREATMENT OF ADULTS WITH PROGRESSING DESMOID TUMORS.
Filter by:
![](https://dtrf.org/wp-content/uploads/2023/09/COTS_exciting-year_Kaspr_for-newsletter-720x450.jpg)
November 22, 2022
Desmoid Tumors In The Spotlight At The 2022 Connective Tissue Oncology Society (CTOS) Conference
![](https://dtrf.org/wp-content/uploads/2022/10/Kasper_Gounder_Gronchi_CTOS_PeerView_Newsroom-720x450.jpg)
October 27, 2022
DTRF And PeerView Offer CME Accredited Course At CTOS On Treatment Of Desmoid Tumors
Read More about DTRF And PeerView Offer CME Accredited Course At CTOS On Treatment Of Desmoid Tumors
![](https://dtrf.org/wp-content/uploads/2023/09/Jeanne_CTOS-Desmoids-Webinar_Newsroom-720x450.jpg)
October 20, 2022
DTRF Exec. Dir. Presents At CTOS Webinar On Desmoid Tumors, The CTOS 2022 “Sarcoma Of The Year”
![](https://dtrf.org/wp-content/uploads/2023/09/post-fallback.png)
![](https://dtrf.org/wp-content/uploads/2023/09/DTAM-2022_Standard-Promo-Image_TW_Newsroom-720x450.jpg)
September 30, 2022
Desmoid Tumor Awareness Month 2022 Comes To A Close
Read More about Desmoid Tumor Awareness Month 2022 Comes To A Close
![](https://dtrf.org/wp-content/uploads/2023/09/THANK-YOU-for-joining-us_2022-Weekend-close_TW_Newsroom-720x450.png)
September 27, 2022
DTRF Hosts Successful 2022 Virtual DTRF “Together We Will” Weekend
Read More about DTRF Hosts Successful 2022 Virtual DTRF “Together We Will” Weekend